

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHY) is an innovative Australian biotechnology company with a number of products launched and nearing commercial launch in the pharmaceutical, sexual health and agrochemical sectors.

Starpharma is a world-leader in the development of dendrimer products. Dendrimers are a nanoscale polymer that is well suited to drug-delivery, pharmaceutical and agrochemical uses.

Starpharma has three core development programs: the VivaGel® Portfolio, Drug Delivery including Dendrimer Enhanced Product (DEP™) drug candidates and Agrochemicals, with the Company developing a number of products internally and others via commercial partnerships. Starpharma is based in Melbourne, listed on the ASX and is in the ASX300 Index.

Share Data: 27 February 2015

Share Price AUD	A\$0.515
Market Capitalisation AUD	~A\$164M
Shares Outstanding	319M
Cash as at 28 January AUD	~A\$39.3M Including A\$4.2M R&D incentive
Average ASX Daily Volume	~ 178K shares

RECENT HIGHLIGHTS

- Marketing clearance for VivaGel® condom in New Zealand
- Starpharma's Priostar Glyphosate Patent Allowed in China
- Starpharma raises A\$21.5M through Placement and SPP
- Starpharma receives \$4.2M R&D tax incentive refund
- VivaGel® condom launched in Australian stores
- DEP™ docetaxel - longer duration and increased exposure
- Phase 3 trials of VivaGel® for the prevention of Bacterial Vaginosis (BV) commence (under an FDA SPA)

Starpharma's Dendrimer Platform

VivaGel® Portfolio

Drug Delivery

Agrochemicals

Condom coating
STI prevention



Bacterial vaginosis

Symptomatic relief
BV prevention

Dendrimer enhanced nanoparticles (DEP™)

DEP™ docetaxel
DEP™ oxaliplatin



Partnered projects



Improved agrochemicals



Development Programs

Starpharma's lead product is VivaGel®, a gel-based formulation of a proprietary antimicrobial dendrimer.

The company has achieved a number of recent major milestones across the VivaGel® portfolio. The VivaGel® condom has been officially launched in Australia and is now available for purchase across the country.

Important clinical and regulatory developments have also been achieved for the VivaGel® bacterial vaginosis (BV) stand-alone product, with the Company's Phase 3 trials progressing well after receiving a Special Protocol Assessment (SPA) from the US Food and Drug Administration (FDA).

Starpharma has both partnered and internal programs in Drug Delivery. Partners include AstraZeneca and Lilly. Starpharma also has a clinical stage dendrimer docetaxel (DEP™ docetaxel) in development. DEP™ docetaxel has already demonstrated significant advantages including improved anticancer efficacy (in animals), significant tumour targeting and reduced toxicity and is now in phase 1 human trials with positive initial findings and pharmacokinetics.

VivaGel® for Bacterial Vaginosis

Starpharma has commenced phase 3 clinical trials of VivaGel® for the prevention of recurrent bacterial vaginosis (BV). The trial design received binding approval from the US FDA under a SPA, which reduces regulatory risk for the clinical program. The company is also pursuing regulatory approval and is in active discussions with commercial partners for the use of VivaGel® for the symptomatic relief of BV in various markets outside the US and has commercial discussions underway.

BV is the most common vaginal infection worldwide, affecting an estimated 30% of the adult female population in the US, and more than 50% in some US populations. The global market for treatment and prevention of recurrence of BV is estimated to be in excess of US\$1bn.

Starpharma VivaGel® Coated Condom

The VivaGel® condom is now available for purchase throughout Australia under Ansell's brand, LifeStyles® Dual Protect™.

Starpharma has signed separate licence agreements with Ansell Limited and Okamoto Industries Inc. to market a value-added VivaGel® condom with marketing clearance achieved in New Zealand.

Starpharma's partner outside Japan, Ansell, is ranked number two globally in terms of condom sales, marketing a number of leading brands.

Okamoto is the market leader for condoms sold in Japan, the world's second-largest condom market.

This represents an important milestone for Starpharma being the first commercial product launch from the VivaGel® portfolio, and a world-first product in the battle against sexually transmitted infections. The company will receive royalty payments on sales under these agreements.

Drug Delivery

Dendrimers have shown significant commercial applicability in drug delivery.

Starpharma has an internal program for the development of enhanced formulations of important cancer therapies. Its dendrimer-enhanced docetaxel, DEP™ docetaxel commenced a phase 1 trial in 2014 and preliminary analyses of the pharmacokinetics have shown intended longer duration and increased exposure. Docetaxel is a US\$3 billion anti-cancer product used to treat breast, lung and prostate cancer.

The reformulation of market leading chemotherapies with a suite of Starpharma's dendrimers has shown a number of advantages including improved efficacy, tumour targeting and improved water solubility, potentially allowing for the development of a novel, improved formulation of this important cancer drug. A second product DEP™ oxaliplatin, a reformulation of the chemotherapeutic commonly used to treat colorectal cancer, is in preclinical development.

Starpharma has commercial agreements with a number pharmaceutical companies that are actively exploring the use of dendrimers to enhance and improve their pharmaceutical products. Partners include AstraZeneca and Lilly. AstraZeneca, recently entered into a second, expanded agreement applying DEP™ technology to a cancer drug from its pipeline.

Agrochemical and crop protection

The company has also expanded commercialisation of dendrimer opportunities in the agrochemical sector with agreements with a number of major firms including Adama and via its internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

Partnering

Starpharma's business strategy is to advance lead products internally, in parallel with an active partnering program. It has partnerships with around half of the world's top-10 pharmaceutical companies and a similar number of the world's leading agrochemical companies. This strategy allows the company to accelerate its product development through multiple commercial relationships and progress the commercialisation of multiple products concurrently. As a result, Starpharma has a deep and robust portfolio of products at various stages of development.



For more information: www.starpharma.com

Jackie Fairley	Chief Executive Officer	+61 3 8532 2704
Nigel Baade	CFO & Company Secretary	+61 3 8532 2704
Rebecca Wilson	Media and Investor Relations	+61 3 8866 1200

jackie.fairley@starpharma.com

nigel.baade@starpharma.com

rwilson@buchanwe.com.au

This document may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward looking statements, including those predicting the timing and results of clinical trials, interpretation and implications of such results, availability or adequacy of financing, the sales and marketing of commercial products or the efficacy of products. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.